E.I. Eboulet

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

Sacha I. Rothschild, Alfred Zippelius, E.I. Eboulet et al. · Journal of Clinical Oncology · 2021 · 341 citations

Medicine, Oncology, Pharmacotherapy +13

SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.

Sacha I. Rothschild, Alfred Zippelius, E.I. Eboulet et al. · Journal of Clinical Oncology · 2020 · 39 citations

Medicine, Oncology, Pharmacology +17

Impact of Early Prophylactic Cranial Irradiation With Hippocampal Avoidance on Neurocognitive Function in Patients With Limited Disease Small Cell Lung Cancer. A Multicenter Phase 2 Trial (SAKK 15/12)

Hansjörg Vees, Francesca Caparrotti, E.I. Eboulet et al. · International Journal of Radiation Oncology*Biology*Physics · 2020 · 37 citations · Full text

Medicine, Oncology, Radiation Oncology +15

Impact of CT convolution kernel on robustness of radiomic features for different lung diseases and tissue types

S. Denzler, Diem Vuong, Marta Bogowicz et al. · British Journal of Radiology · 2021 · 33 citations

Medicine, Oncology, Radiology +17

Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)

Yannis Metaxas, Martin Früh, E.I. Eboulet et al. · Annals of Oncology · 2020 · 32 citations · Full text

Medicine, Oncology, Pharmacotherapy +16